ClinicalTrials.gg
CompletedNCT01957579Updated Jun 12, 2017Results posted

A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies

A Phase 1 interventional study of MEDI-551 in Blood Cancer and Advanced B Cell Malignancies, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years to 130 Years. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled May 2011, registered Oct 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
20 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Hematologic Neoplasms with a site in Japan — 5 open to participants now, 6 under way, 1 of them phase 3. Hematologic Neoplasms · Japan.

Enrollment
14th of 18
32 · median 96
Started
2011
the only one that year
Phase 1
7 of 19
none open now
Registered
7th of 19
by date
Lead sponsor
2 of 19
AstraZeneca

Among the 19 studies in Hematologic Neoplasms with a site in Japan, this one is the 14th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 1, and was the 7th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

5 of the 19 studies in Hematologic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 20 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Hematologic Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.

03

Conditions studied

  • Blood Cancer
  • Advanced B Cell Malignancies

Keywords

  • Phase I
  • advanced
  • B cell malignancies
  • dose escalation
  • CD19
  • Japanese
04

Who can participate

Ages eligible
20 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese men or women at least 20 years of age
  • confirmed CLL (excluding small lymphocytic lymphoma (SLL)), DLBCL, FL, or MM.
  • Performance Status ≥70;
  • of ≥12 weeks

Exclusion criteria

Exclusion Criteria:

  • Any available standard known to be life-prolonging or life-saving
  • Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancer
  • Previous therapy directed against CD19, such as monoclonal antibodies or MAb conjugates
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    MEDI-551

    Drug: MEDI-551

Interventions

  • MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events

    Time frame: From baseline to 30 days after the last dose of study drug

Secondary outcomes

  1. Number of Participants With Dose Limiting Toxicities

    A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.

    Time frame: From baseline to 28 days after the first dose of study drug

  2. Maximum Tolerated Dose

    A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.

    Time frame: From baseline to 28 days after the first dose of study drug

  3. MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 0 (pre-dose)

  4. MEDI-551 Trough Concentration Levels at Day 7

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 7

  5. MEDI-551 Trough Concentration Levels at Day 28

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 28

  6. MEDI-551 Trough Concentration Levels at Day 56

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 56

  7. MEDI-551 Trough Concentration Levels at Day84

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 84

  8. MEDI-551 Trough Concentration Levels at Day 112

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 112

  9. MEDI-551 Trough Concentration Levels at Day 140

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 140

  10. MEDI-551 Trough Concentration Levels at Day 168

    Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

    Time frame: Day 168

  11. Anti-MEDI-551 Antibodies

    Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.

    Time frame: From baseline to 30 days after the last dose of study drug

  12. Number of Participants With Tumour Response in FL Patients

    Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

    Time frame: From the baseline to 30 days after the last dose of study drug

  13. Number of Participants With Tumour Response in DLBCL Patients

    Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

    Time frame: From the baseline to 30 days after the last dose of study drug

  14. Number of Participants With Tumour Response in CLL Patients

    Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008). CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: \<4000/μL; Marrow: Normocellular, \<30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: \>100000/μL; Hemoglobin: \>11.0 g/dL; Neutrophils: \>1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met. Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules. Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: \>11.0 g/dL or increase ≥50% over baseline; Neutrophils: \>1500/μL or \>50% improvement over baseline.

    Time frame: From the baseline to 30 days after the last dose of study drug

  15. Number of Participants With Tumour Response in MM Patients

    Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006). CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.

    Time frame: From the baseline to30 days after the last dose of study drug

07

Results

Posted Apr 10, 2017

Participant flow

First patient enrolled on 25 May 2011. Last patient last visit on 15 September 2015.

Participant flow — Overall Study
Milestone2 mg/kg4 mg/kg8 mg/kg12 mg/kg
Started3746
Completed3626
Not completed0120
Withdrew: Withdrawal of concent0100
Withdrew: Death0020

Outcome measures

PrimaryNumber of Participants With Adverse Events
Time frame:
From baseline to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Adverse Events
Participants2 mg/kg4 mg/kg8 mg/kg12 mg/kg
At least 1 Adverse Events (AE)3646
At least 1 AE of CTCAE Grade 3 or higher2213
At least 1 Serious Adverse Events (SAE)1000
SecondaryNumber of Participants With Dose Limiting Toxicities

A MEDI-551 treatment-related AE of any toxicity grade that lead to an inability to receive a full cycle (2 doses) of MEDI-551, or, any Grade 3 or higher toxicity that could not be reasonably ascribed to another cause, such as disease progression or accident.

Time frame:
From baseline to 28 days after the first dose of study drug
Reported as:
Number · Participants
Number of Participants With Dose Limiting Toxicities
Participants2 mg/kg4 mg/kg8 mg/kg12 mg/kg
At least 1 Dose Limiting Toxicity0102
CTCAE Grade 3 or higher non-hematologic toxicity0101
CTCAE Grade 3 or higher hematologic toxicity0001
SecondaryMaximum Tolerated Dose

A dose was considered non-tolerated and dose escalation stopped if ≥2 of up to 6 evaluable patients experienced a DLT at any dose level. MTD is the last dose level before the non-tolerated dose.

Time frame:
From baseline to 28 days after the first dose of study drug
Reported as:
Number · mg/kg
Maximum Tolerated Dose
mg/kgMEDI-551
Maximum Tolerated Dose8
SecondaryMEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 0 (pre-dose)
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 0 (Pre-dose)NA ± NANA ± NANA ± NANA ± NA
SecondaryMEDI-551 Trough Concentration Levels at Day 7

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 7
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 7
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 721.3 ± 8.6539.2 ± 9.1391.9 ± 31.1104 ± 29.0
SecondaryMEDI-551 Trough Concentration Levels at Day 28

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 28
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 28
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 2823.2 ± 5.8236.2 ± 5.34103 ± 29.0115 ± 21.3
SecondaryMEDI-551 Trough Concentration Levels at Day 56

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 56
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 56
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 5622.0 ± 4.9233.2 ± 6.9289.5 ± 13.9114 ± 33.1
SecondaryMEDI-551 Trough Concentration Levels at Day84

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 84
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day84
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day8421.7 ± 4.4033.7 ± 4.2491.6 ± 9.25103 ± 26.3
SecondaryMEDI-551 Trough Concentration Levels at Day 112

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 112
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 112
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 11222.9 ± 3.1035.3 ± 5.0785.5 ± NA114 ± 64.4
SecondaryMEDI-551 Trough Concentration Levels at Day 140

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 140
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 140
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 14022.1 ± NA36.3 ± 10.586.1 ± NA117 ± 62.0
SecondaryMEDI-551 Trough Concentration Levels at Day 168

Lower limit of quantification for MEDI-551 was 0.1 μg/mL.

Time frame:
Day 168
Reported as:
Mean · μg/mL
MEDI-551 Trough Concentration Levels at Day 168
μg/mL2 mg/kg4 mg/kg8 mg/kg12 mg/kg
MEDI-551 Trough Concentration Levels at Day 16820.0 ± NA31.4 ± 8.3094.1 ± NA82.1 ± NA
SecondaryAnti-MEDI-551 Antibodies

Only 1 patient was tested positive for ADA at pre-dose of Cycle 1 Day 1. However, it was considered as false-positive because the titer value was close to the cut point, and this patient was tested negative for ADA at all subsequent cycles post-baseline.

Time frame:
From baseline to 30 days after the last dose of study drug
Reported as:
Number · Participants
Anti-MEDI-551 Antibodies
Participants2 mg/kg4 mg/kg8 mg/kg12 mg/kg
positive at least 1 time point0010
negative at all time points3736
SecondaryNumber of Participants With Tumour Response in FL Patients

Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

Time frame:
From the baseline to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Tumour Response in FL Patients
Participants2 mg/kg (FL)4 mg/kg (FL)8 mg/kg (FL)12 mg/kg (FL)
Number of Participants With Tumour Response in FL Patients2322
SecondaryNumber of Participants With Tumour Response in DLBCL Patients

Tumour response is defined as complete remission (CR) or partial remission (PR) (Cheson BD et al 2007). CR: Nodal Masses: (a) FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative; (b) Variably FDG-avid or PET negative; regression to normal size on CT; Spleen, Liver: Not palpable, nodules disappeared. Bone Marrow: Infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry should be negative. PR: Nodal Masses: ≥50% decrease in sum of the product of the diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes; (a) FDG-avid or PET positive prior to therapy; ≥1 PET positive at previously involved site; (b) Variably FDG-avid or PET negative; regression on CT. Spleen, Liver: ≥50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone Marrow: Irrelevant if positive prior to therapy; cell type should be specified.

Time frame:
From the baseline to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Tumour Response in DLBCL Patients
Participants2 mg/kg (DLBCL)4 mg/kg (DLBCL)8 mg/kg (DLBCL)12 mg/kg (DLBCL)
Number of Participants With Tumour Response in DLBCL Patients—012
SecondaryNumber of Participants With Tumour Response in CLL Patients

Tumour response is defined as complete remission (CR) or partial remission (PR) (Hallek M et al 2008). CR: all of the following criteria have to be met, and patients have to lack disease-related constitutional symptoms; Lymphadenopathy: None; Hepatomegaly: None; Splenomegaly: None; Blood lymphocytes: \<4000/μL; Marrow: Normocellular, \<30%lymphocytes, no B-lymphoid nodules, hypocellular marrow defines CR with incomplete marrow recovery; Platelet count: \>100000/μL; Hemoglobin: \>11.0 g/dL; Neutrophils: \>1500/μL PR: at least 2 of the criteria of group A plus 1 of the criteria of group B have to be met. Group A: Lymphadenopathy: Decrease ≥50%; Hepatomegaly: Decrease ≥50%; Splenomegaly: Decrease ≥50%; Blood lymphocytes: Decrease ≥50% from baseline; Marrow: 50% reduction in marrow infiltrate, or B-lymphoid nodules. Group B: Platelet count: 100000/μL or increase ≥50% over baseline; Hemoglobin: \>11.0 g/dL or increase ≥50% over baseline; Neutrophils: \>1500/μL or \>50% improvement over baseline.

Time frame:
From the baseline to 30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Tumour Response in CLL Patients
Participants2 mg/kg (CLL)4 mg/kg (CLL)8 mg/kg (CLL)12 mg/kg (CLL)
Number of Participants With Tumour Response in CLL Patients1——0
SecondaryNumber of Participants With Tumour Response in MM Patients

Tumour response is defined as complete response (CR) or partial response (PR) (Durie M et al 2006). CR: Negative immunofixation on the serum and urine, and Disappearance of any soft tissue plasmacytomas and 5% or less plasma cells in bone marrow PR: ≥50% reduction of serum M-protein and reduction in 24-h urinary M-protein by ≥90% or to \<200mg per 24 h. If the serum and urine M-protein are unmeasurable, a ≥50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, ≥50% reduction in plasma cells is required in place of M-protein, provided baseline bone marrow plasma cell percentage was ≥30%. In addition to the above listed criteria, if present at baseline, a ≥50% reduction in the size of soft tissue plasmacytomas is also required.

Time frame:
From the baseline to30 days after the last dose of study drug
Reported as:
Number · Participants
Number of Participants With Tumour Response in MM Patients
Participants2 mg/kg (MM)4 mg/kg (MM)8 mg/kg (MM)12 mg/kg (MM)
Number of Participants With Tumour Response in MM Patients—0——

Adverse events

Collected over AEs were collected throughout the study, from informed consent until the end of 30 days after study treatment. The follow-up period is defined as 3 months after study treatment is discontinued.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 mg/kg—1/3 (33.3%)3/3 (100%)
4 mg/kg—0/7 (0%)6/7 (85.7%)
8 mg/kg—0/4 (0%)4/4 (100%)
12 mg/kg—0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
Event2 mg/kg4 mg/kg8 mg/kg12 mg/kg
EpiglottitisInfections and infestations1/30/70/40/6
Most frequent other events
Showing 10 of 50
Most frequent other events
Event2 mg/kg4 mg/kg8 mg/kg12 mg/kg
HypertriglyceridaemiaMetabolism and nutrition disorders1/31/74/40/6
Infusion related reactionInjury, poisoning and procedural complications2/31/73/43/6
White blood cell count decreasedInvestigations2/32/70/40/6
Lymphocyte count decreasedInvestigations1/32/70/40/6
Neutrophil count decreasedInvestigations1/32/70/40/6
Aspartate aminotransferase increasedInvestigations1/30/70/40/6
Blood lactate dehydrogenase increasedInvestigations1/30/70/40/6
Blood triglycerides increasedInvestigations1/30/70/40/6
NasopharyngitisInfections and infestations1/30/71/41/6
Upper respiratory tract infectionInfections and infestations1/30/70/41/6

Baseline characteristics

All patients who received at least 1 dose of MEDI-551.

Age, Continuous
Age, Continuous(Years)2 mg/kg4 mg/kg8 mg/kg12 mg/kgTotal
Mean50.3 ± 8.157.4 ± 10.567.0 ± 8.767.3 ± 11.461.3 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)2 mg/kg4 mg/kg8 mg/kg12 mg/kgTotal
Female250310
Male124310
Disease Type
Disease Type(Participants)2 mg/kg4 mg/kg8 mg/kg12 mg/kgTotal
CLL10012
DLBCL02226
FL242311
MM01001
08

Study locations

3 sites
  • Research Site
    Fukuoka-shi, Japan
  • Research Site
    Isehara-shi, Japan
  • Research Site
    Nagoya-shi, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Sep 2015, 51 months.

Results were first posted in Apr 2017, 1 year 6 months after primary completion.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 51 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2013
First posted
Oct 8, 2013
StartActual
May 25, 2011
Primary completionActual
Sep 15, 2015
CompletionActual
Sep 15, 2015
Results first posted
Apr 10, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01957579
Lead sponsor
AstraZeneca
Collaborators
MedImmune LLC
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
May 25, 2011
Primary completion
Sep 15, 2015
Completion
Sep 15, 2015
Results posted
Apr 10, 2017
Last update
Jun 12, 2017

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion